Status:
ACTIVE_NOT_RECRUITING
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
Lead Sponsor:
Geneplus-Beijing Co. Ltd.
Collaborating Sponsors:
Chinese PLA General Hospital
Conditions:
Early Detection of Cancer
Eligibility:
All Genders
45+ years
Brief Summary
This is a observational, multicenter study, monitoring the circulating tumor DNA (ctDNA) in people who is at risk of cancers，assessing the sensitivity and specificity of ctDNA detection in early scree...
Detailed Description
2000 patients with positive tumor protein markers or cancer screening were recruited. All patients were tested for ctDNA at enrollment and followed up at 6 months and 1 year. The study was completed a...
Eligibility Criteria
Inclusion
- Patients aged at or over 45 years old.
- Patients who with one or more of the following situations:
- In AFP (\>20UG/L), CA125 (\>70U/ml), CEA (\>7ng/ml) and CA199 (\>60U/ml), more than one item was abnormal for two consecutive times within one month.
- Patients with viral hepatitis (Hepatitis B / C surface antigen positive with liver function damage.
- Patients with liver nodules detected by ultrasound and hemangioma excluded.
- Patients with compensated cirrhosis.
- CA125\>35U/ml and HE4 was abnormal (the reference value of HE4 in premenopausal and postmenopausal women was 68.96 pmol/L and 114.90 pmol/L respectively).
- Patients with ovarian masses found by ultrasonography (premenopausal \> 5cm, postmenopausal \> 3.5cm).
- Patients with pancreatic space-occupying found by ultrasonography.
- Patients with BI-RADS grade 4 or above by ultrasound or mammography.
- CA125\>35U/ml and BI-RADS above grade 3 by ultrasound or mammography.
- CA153\>25U/ml and BI-RADS above grade 3 by ultrasound or mammography.
- Family genetic history of breast cancer and ovarian cancer, and BI-RADS above grade 3 by ultrasound or mammography.
- Patients with a positive fecal occult blood test and haemorrhoids excluded
- Patients with a positive fecal occult blood test and positive CEA
- More than 2 items were abnormal in PGI, PGR and G-17 (criteria: PGI≤70 UG/L, PGR≤7.0, G-17≤1 pmol/L or G-17≥15 pmol/L).
- Ability to collect specimens from each time point and provide corresponding clinical information.
- Understand the research plan and voluntarily participate in the study, sign the informed consent form.
Exclusion
- Patients with previous or present cancer.
- Patients with serious diseases, especially those with a survival period of less than 3 years.
- Patients with factors that affect the diagnosis of the disease (such as MRI related cardiac pacemakers, ferromagnetic implants, etc.).
- Patients with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Women who are pregnant or preparing for pregnancy.
- Patients who voluntarily withdraw for any reason.
- Patients who cannot complete the research plan
Key Trial Info
Start Date :
November 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
757 Patients enrolled
Trial Details
Trial ID
NCT04405557
Start Date
November 12 2019
End Date
December 31 2026
Last Update
September 4 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
2
Shenzhen People's Hospital
Shenzhen, Guangdong, China, 518020
3
Henan Provincial People's Hospital
Zhengzhou, Henan, China, 450003
4
Xiangya Hospital Central South University
Changsha, Hunan, China, 410008